Sun Pharma, an Indian multinational pharmaceutical company, agreed to acquire the remaining stake in Taro Pharmaceutical Industries, an Israeli research-based pharmaceutical manufacturer, for $454m. "Over the years, with Sun Pharma's strategic interventions, Taro has remained a key player in the generic dermatology market in a challenging environment. Post completion of the merger, the combined entity will firmly move forward, leveraging its global strengths and capabilities to better serve the needs of patients and healthcare professionals," Dilip Shanghvi, Sun Pharma Managing Director.